Learning Objectives: 

1. Describe the methods and findings of the TULIP-2 trial.

2. Identify instances where anifrolumab may be particularly useful.

Session date: 
09/21/2021 - 8:30am to 9:30am CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Emily Peninger, M.D.